Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

Modeling Alzheimer’s: The neuronal code is finally cracked

A comprehensive 3D model of human neuronal pathophysiology leading to Alzheimer’s disease is now complete. The final model provides confirmation of how amyloid plaque build-up and tau neurofibrillary tangles are not just related to onset of disease, but that amyloid hastens tau pathology, according to a letter published online Oct. 12 in Nature.

Lymphoseek FDA approved for lymphatic malignancy in all solid tumors

Navidea Biopharmaceutical’s supplemental new drug application for sentinel lymph-node mapping agent Lymphoseek (technetium Tc 99m tilmanocept) has now been approved for detection of lymph node involvement in all solid tumors, the company announced today.

Molecular imaging of stroke

While CT and MR are still the mainstays of detecting ischemic stroke, several SPECT and PET imaging techniques have been developed and are on the way to add comprehensive clinical information in the case of cerebrovascular disease. With this in mind, hybrid imaging such as PET/MR could provide a best-possible map of variables involved in stroke, according to a review published Oct. 9 in the Journal of Nuclear Medicine.

Thumbnail

WMIS reveals new intraoperative imaging research

A workshop for intraoperative imaging including discussion about the most novel techniques in the discipline was recently conducted during the Congress of the World Molecular Imaging Society (WMIS) in Seoul, Korea. The workshop featured presentations on intraoperative and real-time use of laser light and light-emitting agents, CCD cameras and ultraminiaturized microscopes, the WMIS announced yesterday.

Thumbnail

Specialized eyes of mantis shrimp show cancer in new light

A new and tiny camera steals from the sight of the powerful, all-seeing mantis shrimp in order to detect cancers that we currently cannot. The new and rather simple system relies on polarized light, which these shrimps can see in spades, to create a whole new dimension of cancer imaging, according to this report from Smithsonian.

Thumbnail

New SPECT database holds 100K scans for psychiatric study

A searchable database of 100,000 SPECT neuroimaging studies that incorporates scans from 111 different countries and subjects ranging from nine months to 101 years old was introduced today by Amen Clinics, a network of psychiatric clinics based in Costa Mesa, Calif. The intention of the database is to promote open collaboration and interdisciplinary study of psychiatric and related disorders.

Thumbnail

WMIS highlights from World Nuclear Medicine and Molecular Imaging Week

Saturday marked the final day of the 2014 Nuclear Medicine and Molecular Imaging Week and, to celebrate, the World Molecular Imaging Society (WMIS) announced highlights of the recent 7th World Molecular Imaging Congress held in Seoul, Korea.

Thumbnail

Exceptional responders may hold genetic keys to better cancer treatments

The National Cancer Institute has mounted a search for people who are dramatic outliers in their response to cancer therapies in an effort to improve treatments for common malignancies.